TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-month Double-blind, Randomized, Multicenter, Active-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Interferon ß-1a (Avonex) Administered im Once Weekly in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
Brief Summary: This study assessed the safety, tolerability, and efficacy of 2 doses of oral fingolimod versus interferon β-1a to reduce the frequency of relapses in patients with relapsing-remitting multiple sclerosis.


Options:
A: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab | Arm Label: Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2
B: Arm Label: Fingolimod 1.25 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod 1.25 mg | Arm Label: Fingolimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod 0.5 mg | Arm Label: Interferon β-1a 30 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon β-1a 30 µg | Intervention Type: DRUG; Name: Fingolimod 1.25 mg; Assigned to Arm(s): Fingolimod 1.25 mg | Intervention Type: DRUG; Name: Fingolimod 0.5 mg; Assigned to Arm(s): Fingolimod 0.5 mg | Intervention Type: DRUG; Name: Interferon β-1a 30 µg; Assigned to Arm(s): Interferon β-1a 30 µg
C: Arm Label: Rebif®; Type: EXPERIMENTAL; Interventions: Drug: Rebif® | Arm Label: Copaxone®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Copaxone® | Intervention Type: DRUG; Name: Rebif®; Assigned to Arm(s): Rebif® | Intervention Type: DRUG; Name: Copaxone®; Assigned to Arm(s): Copaxone®
D: Arm Label: Fingolimod 1.25 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod 1.25 mg | Arm Label: Fingolimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod 0.5 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fingolimod 1.25 mg; Assigned to Arm(s): Fingolimod 1.25 mg | Intervention Type: DRUG; Name: Fingolimod 0.5 mg; Assigned to Arm(s): Fingolimod 0.5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-month Double-blind, Randomized, Multicenter, Active-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Interferon ß-1a (Avonex) Administered im Once Weekly in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
Brief Summary: This study assessed the safety, tolerability, and efficacy of 2 doses of oral fingolimod versus interferon β-1a to reduce the frequency of relapses in patients with relapsing-remitting multiple sclerosis.


Options:
A: Arm Label: Fingolimod (FTY720) 1.25 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo/Fingolimod (FTY720); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Fingolimod (FTY720) 5.0 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): Fingolimod (FTY720) 1.25 mg/day, Fingolimod (FTY720) 5.0 mg/day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Fingolimod (FTY720)
B: Arm Label: Fingolimod 1.25 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod 1.25 mg | Arm Label: Fingolimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod 0.5 mg | Arm Label: Interferon β-1a 30 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon β-1a 30 µg | Intervention Type: DRUG; Name: Fingolimod 1.25 mg; Assigned to Arm(s): Fingolimod 1.25 mg | Intervention Type: DRUG; Name: Fingolimod 0.5 mg; Assigned to Arm(s): Fingolimod 0.5 mg | Intervention Type: DRUG; Name: Interferon β-1a 30 µg; Assigned to Arm(s): Interferon β-1a 30 µg
C: Arm Label: Fingolimod 1.25 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod 1.25 mg | Arm Label: Fingolimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod 0.5 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fingolimod 1.25 mg; Assigned to Arm(s): Fingolimod 1.25 mg | Intervention Type: DRUG; Name: Fingolimod 0.5 mg; Assigned to Arm(s): Fingolimod 0.5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-month Double-blind, Randomized, Multicenter, Active-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Interferon ß-1a (Avonex) Administered im Once Weekly in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
Brief Summary: This study assessed the safety, tolerability, and efficacy of 2 doses of oral fingolimod versus interferon β-1a to reduce the frequency of relapses in patients with relapsing-remitting multiple sclerosis.


Options:
A: Arm Label: Rebif®; Type: EXPERIMENTAL; Interventions: Drug: Rebif® | Arm Label: Copaxone®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Copaxone® | Intervention Type: DRUG; Name: Rebif®; Assigned to Arm(s): Rebif® | Intervention Type: DRUG; Name: Copaxone®; Assigned to Arm(s): Copaxone®
B: Arm Label: Fingolimod 1.25 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod 1.25 mg | Arm Label: Fingolimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod 0.5 mg | Arm Label: Interferon β-1a 30 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon β-1a 30 µg | Intervention Type: DRUG; Name: Fingolimod 1.25 mg; Assigned to Arm(s): Fingolimod 1.25 mg | Intervention Type: DRUG; Name: Fingolimod 0.5 mg; Assigned to Arm(s): Fingolimod 0.5 mg | Intervention Type: DRUG; Name: Interferon β-1a 30 µg; Assigned to Arm(s): Interferon β-1a 30 µg
C: Arm Label: Fingolimod (FTY720) 1.25 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo/Fingolimod (FTY720); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Fingolimod (FTY720) 5.0 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): Fingolimod (FTY720) 1.25 mg/day, Fingolimod (FTY720) 5.0 mg/day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Fingolimod (FTY720)
D: Intervention Type: DRUG; Name: BG00012; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-month Double-blind, Randomized, Multicenter, Active-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Interferon ß-1a (Avonex) Administered im Once Weekly in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
Brief Summary: This study assessed the safety, tolerability, and efficacy of 2 doses of oral fingolimod versus interferon β-1a to reduce the frequency of relapses in patients with relapsing-remitting multiple sclerosis.


Options:
A: Arm Label: Interferon beta-1a 44 mcg SC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta-1a, Drug: Ocrelizumab-matching placebo | Arm Label: Ocrelizumab; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab, Drug: Interferon beta-1a-matching placebo | Intervention Type: DRUG; Name: Interferon beta-1a; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab-matching placebo; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab | Intervention Type: DRUG; Name: Interferon beta-1a-matching placebo; Assigned to Arm(s): Ocrelizumab
B: Arm Label: Fingolimod 1.25 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod 1.25 mg | Arm Label: Fingolimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod 0.5 mg | Arm Label: Interferon β-1a 30 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon β-1a 30 µg | Intervention Type: DRUG; Name: Fingolimod 1.25 mg; Assigned to Arm(s): Fingolimod 1.25 mg | Intervention Type: DRUG; Name: Fingolimod 0.5 mg; Assigned to Arm(s): Fingolimod 0.5 mg | Intervention Type: DRUG; Name: Interferon β-1a 30 µg; Assigned to Arm(s): Interferon β-1a 30 µg
C: Arm Label: Interferon beta-1a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta-1a, Drug: Placebo to ozanimod | Arm Label: Ozanimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ozanimod, Drug: Placebo to interferon beta-1a | Arm Label: Ozanimod 1 mg; Type: EXPERIMENTAL; Interventions: Drug: Ozanimod, Drug: Placebo to interferon beta-1a | Intervention Type: DRUG; Name: Ozanimod; Assigned to Arm(s): Ozanimod 0.5 mg, Ozanimod 1 mg | Intervention Type: DRUG; Name: Interferon beta-1a; Assigned to Arm(s): Interferon beta-1a | Intervention Type: DRUG; Name: Placebo to ozanimod; Assigned to Arm(s): Interferon beta-1a | Intervention Type: DRUG; Name: Placebo to interferon beta-1a; Assigned to Arm(s): Ozanimod 0.5 mg, Ozanimod 1 mg
D: Arm Label: GA 20 mg/mL every day; Type: ACTIVE_COMPARATOR; Interventions: Drug: GA 20 mg/mL | Arm Label: GA 40 mg/mL 3 times a week; Type: EXPERIMENTAL; Interventions: Drug: GA 40 mg/mL | Intervention Type: DRUG; Name: GA 20 mg/mL; Assigned to Arm(s): GA 20 mg/mL every day | Intervention Type: DRUG; Name: GA 40 mg/mL; Assigned to Arm(s): GA 40 mg/mL 3 times a week

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Natural History Study of Multidrug-Resistant Tuberculosis Strains and Host Susceptibility Genes in Korean Patients With Pulmonary Tuberculosis
Brief Summary: This study, conducted in Korea, will examine why some people are more susceptible to tuberculosis (TB) than others and why some strains of M tuberculosis (the bacteria that causes TB) are more difficult to treat or become resistant to drug treatments. The study will compare blood samples and other medical information from patients with different kinds of tuberculosis and with healthy volunteers to identify patient and bacterial characteristics that contribute to disease susceptibility, treatment failure, disease recurrence and multi-drug resistance.

Healthy volunteers and patients with tuberculosis who are 20 years of age or older may be eligible for this study. Subjects are recruited from among patients receiving treatment for tuberculosis at the National Masan Tuberculosis Hospital in the Republic of Korea and from healthy people visiting government health care centers for annual medical checkups. The latter include people who have had TB but are cured; people who have been exposed to TB, but currently have no signs of disease; and those who have not been exposed to TB.

Participants with tuberculosis undergo the following tests and procedures:

* Medical history, including past treatments for TB, and review of medical records
* Interview about home and work
* Sputum collection to test for the kind of TB bacteria present and for genetic studies of the bacteria
* Drug treatment for TB
* Blood draws as part of regular patient care, for HIV testing, and for genetic studies
* Chest x-rays as part of routine patient care
* In patients with recurrent disease, examination of the strains from both bouts of disease to determine if it is a recurrence of the same organism or infection with a new strain.

Healthy volunteers undergo the following tests and procedures:

* Brief medical history
* Blood draw to look for exposure to TB and for genetic studies
* Review of previous x-ray to look for active TB


Options:
A: Arm Label: LAM plus standard care; Type: EXPERIMENTAL; Interventions: Device: Urine LAM strip test | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Urine LAM strip test; Assigned to Arm(s): LAM plus standard care
B: Intervention Type: DEVICE; Name: Alere "Determine" lateral-flow urine lipoarabinomannan assay; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Alere "Clearview" ELISA urine LAM assay; Assigned to Arm(s): N/A
C: Intervention Type: DEVICE; Name: Alere "Determine" lateral-flow urine lipoarabinomannan assay; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Alere "Clearview" ELISA urine LAM assay; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Cepheid Xpert MTB/Rif assay; Assigned to Arm(s): N/A
D: N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Natural History Study of Multidrug-Resistant Tuberculosis Strains and Host Susceptibility Genes in Korean Patients With Pulmonary Tuberculosis
Brief Summary: This study, conducted in Korea, will examine why some people are more susceptible to tuberculosis (TB) than others and why some strains of M tuberculosis (the bacteria that causes TB) are more difficult to treat or become resistant to drug treatments. The study will compare blood samples and other medical information from patients with different kinds of tuberculosis and with healthy volunteers to identify patient and bacterial characteristics that contribute to disease susceptibility, treatment failure, disease recurrence and multi-drug resistance.

Healthy volunteers and patients with tuberculosis who are 20 years of age or older may be eligible for this study. Subjects are recruited from among patients receiving treatment for tuberculosis at the National Masan Tuberculosis Hospital in the Republic of Korea and from healthy people visiting government health care centers for annual medical checkups. The latter include people who have had TB but are cured; people who have been exposed to TB, but currently have no signs of disease; and those who have not been exposed to TB.

Participants with tuberculosis undergo the following tests and procedures:

* Medical history, including past treatments for TB, and review of medical records
* Interview about home and work
* Sputum collection to test for the kind of TB bacteria present and for genetic studies of the bacteria
* Drug treatment for TB
* Blood draws as part of regular patient care, for HIV testing, and for genetic studies
* Chest x-rays as part of routine patient care
* In patients with recurrent disease, examination of the strains from both bouts of disease to determine if it is a recurrence of the same organism or infection with a new strain.

Healthy volunteers undergo the following tests and procedures:

* Brief medical history
* Blood draw to look for exposure to TB and for genetic studies
* Review of previous x-ray to look for active TB


Options:
A: Intervention Type: DEVICE; Name: Alere "Determine" lateral-flow urine lipoarabinomannan assay; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Alere "Clearview" ELISA urine LAM assay; Assigned to Arm(s): N/A
B: Arm Label: LAM plus standard care; Type: EXPERIMENTAL; Interventions: Device: Urine LAM strip test | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Urine LAM strip test; Assigned to Arm(s): LAM plus standard care
C: N/A
D: Arm Label: Novel; Type: EXPERIMENTAL; Interventions: Procedure: GeneXpert MTB/RIF assay, Procedure: Smear microscopy | Arm Label: Standard; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Smear microscopy | Intervention Type: PROCEDURE; Name: GeneXpert MTB/RIF assay; Assigned to Arm(s): Novel | Intervention Type: PROCEDURE; Name: Smear microscopy; Assigned to Arm(s): Novel, Standard

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pivotal Phase 3 Observer-Blind, Randomized Clinical Trial of the Efficacy and Safety of APF530 Compared to Aloxi For The Prevention of Acute-Onset and Delayed-Onset Chemotherapy-Induced Nausea and Vomiting Following The Administration of Either Moderately or Highly Emetogenic Chemotherapy Regimens
Brief Summary: This randomized phase III trial is studying APF530 and dexamethasone to see how well they work compared with palonosetron and dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for cancer.


Options:
A: Arm Label: Standard therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Aprepitant / Fosaprepitant therapy; Type: EXPERIMENTAL; Interventions: Drug: Aprepitant / Fosaprepitant | Intervention Type: DRUG; Name: Aprepitant / Fosaprepitant; Assigned to Arm(s): Aprepitant / Fosaprepitant therapy
B: Arm Label: Arm I; Type: ACTIVE_COMPARATOR; Interventions: Drug: dexamethasone, Drug: Palonosetron Hydrochloride, Other: placebo | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Drug: APF530, Drug: dexamethasone, Other: placebo | Arm Label: Arm III; Type: EXPERIMENTAL; Interventions: Drug: APF530, Drug: dexamethasone, Other: placebo | Intervention Type: DRUG; Name: APF530; Assigned to Arm(s): Arm II, Arm III | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): Arm I, Arm II, Arm III | Intervention Type: DRUG; Name: Palonosetron Hydrochloride; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm I, Arm II, Arm III
C: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: aprepitant, Drug: cyclophosphamide, Other: placebo | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Drug: aprepitant, Drug: cyclophosphamide, Other: placebo | Intervention Type: DRUG; Name: aprepitant; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Arm I, Arm II | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm I, Arm II
D: Arm Label: Arm A: Aprepitant, Then Placebo; Type: EXPERIMENTAL; Interventions: Drug: Aprepitant, Drug: Placebo | Arm Label: Arm B: Placebo, Then Aprepitant; Type: EXPERIMENTAL; Interventions: Drug: Aprepitant, Drug: Placebo | Intervention Type: DRUG; Name: Aprepitant; Assigned to Arm(s): Arm A: Aprepitant, Then Placebo, Arm B: Placebo, Then Aprepitant | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm A: Aprepitant, Then Placebo, Arm B: Placebo, Then Aprepitant

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Triple Dummy, Placebo-controlled, Randomised, Parallel Group Positron Emission Tomography Study to Investigate the Effects of a 8 Week Administration of GW597599 and Paroxetine Either Alone or in Combination on Regional Cerebral Blood Flow During a Public Speaking Test in Subjects Affected by Social Phobia.
Brief Summary: This six-arm study is being conducted to measure the effect of a combination of paroxetine and vestipitant on the arousal induced by public speaking in Seasonal Effective Disorder (SAD) patients, using functional brain imaging readouts (i.e., WAT(Wave Analysis Technology) PET(Positron Emission Tomography)), after one or eight weeks of treatment. The effect of paroxetine alone after one or eight weeks of treatment will also be measured.


Options:
A: Intervention Type: DRUG; Name: LY686017; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: paroxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
B: Arm Label: Vilazodone; Type: EXPERIMENTAL; Interventions: Drug: Vilazodone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vilazodone; Assigned to Arm(s): Vilazodone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: quetiapine; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: vestipitant; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: paroxetine; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Abbreviated Post-partum Magnesium Sulfate Seizure Prophylaxis in Preeclampsia: A Comparison of 12 and 24 Hour Regimens
Brief Summary: Magnesium sulfate is used for seizure prophylaxis in pregnancies complicated by preeclampsia. There is debate as to how long to continue this therapy after delivery of the pregnancy. Different schemes have been offered to shorten the exposure to magnesium sulfate after delivery, with little data. We seek to investigate the effect of shortened magnesium sulfate therapy on the post-partum recovery phase of mild preeclampsia. Our hypothesis was that shortened therapy (12 hours versus the traditional 24 hours post-partum) has no effect on disease course, and will result in significantly shorter exposure to magnesium sulfate.


Options:
A: Arm Label: Postpartum Magnesium sulfate; Type: EXPERIMENTAL; Interventions: Drug: Magnesium Sulfate | Arm Label: No postpartum treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Magnesium Sulfate; Assigned to Arm(s): Postpartum Magnesium sulfate
B: Intervention Type: DRUG; Name: abbreviation of magnesium sulfate therapy (12 hours versus the traditional 24 hours after delivery); Assigned to Arm(s): N/A
C: Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: SpringFusor Pump | Intervention Type: DEVICE; Name: SpringFusor Pump; Assigned to Arm(s): 1
D: Arm Label: 12 hours of magnesium sulfate; Type: EXPERIMENTAL; Interventions: Drug: Magnesium sulfate 12 hours | Arm Label: 24 hours of magnesium sulfate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Magnesium sulfate 24 hours | Intervention Type: DRUG; Name: Magnesium sulfate 12 hours; Assigned to Arm(s): 12 hours of magnesium sulfate | Intervention Type: DRUG; Name: Magnesium sulfate 24 hours; Assigned to Arm(s): 24 hours of magnesium sulfate

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Optical Coherence Tomography (OCT) Imaging of Patients With Neovascular Age-Related Macular Degeneration (AMD) Treated With Intra-Ocular Lucentis™ (Ranibizumab): PrONTO Study
Brief Summary: The PrONTO Study was designed to evaluate the response of neovascular age-related macular degeneration (AMD) patients to intravitreal Lucentis using Optical Coherence Tomography (OCT) imaging. OCT was then used to determine the need for retreatment after 3 monthly injections of Lucentis. Patients would be followed for 2 years.


Options:
A: Intervention Type: DRUG; Name: Lucentis (Ranibizumab); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab (Lucentis) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab (Lucentis) | Intervention Type: DRUG; Name: Ranibizumab (Lucentis); Assigned to Arm(s): 1, 2

Answer: A